^
    Back
    Association details:
    Biomarker:ARID1A mutation
    Cancer:Ovarian Cancer
    Drug:GSK2816126 (EZH2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Nat Med
    Title:

    Targeting EZH2 methyltransferase activity in ARID1A mutated cancer cells is synthetic lethal

    Excerpt:
    Similarly, GSK126 treatment (50 mg/kg) caused regression of orthotopically xenografted ARID1A mutated TOV21G tumors after first establishing tumors for four weeks followed by two weeks of treatment
    DOI:
    10.1038/nm.3799